Insider Buying: IntelGenx Technologies Corp. (IGXT) CFO Buys $14,400.00 in Stock
IntelGenx Technologies Corp. (OTCMKTS:IGXT) CFO Andre Godin bought 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The shares were acquired at an average price of $0.72 per share, with a total value of $14,400.00. Following the transaction, the chief financial officer now directly owns 79,500 shares of the company’s stock, valued at approximately $57,240. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
IntelGenx Technologies Corp. (OTCMKTS:IGXT) opened at 0.79 on Wednesday. The company’s market capitalization is $50.26 million. IntelGenx Technologies Corp. has a 52 week low of $0.37 and a 52 week high of $1.00. The company’s 50-day moving average price is $0.78 and its 200-day moving average price is $0.60.
IntelGenx Technologies Corp. (OTCMKTS:IGXT) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.01). IntelGenx Technologies Corp. had a negative return on equity of 2.57% and a negative net margin of 2.38%. Equities analysts forecast that IntelGenx Technologies Corp. will post $0.01 earnings per share for the current fiscal year.
A number of brokerages recently commented on IGXT. HC Wainwright set a $2.00 price target on IntelGenx Technologies Corp. and gave the company a “buy” rating in a research note on Thursday, September 15th. Zacks Investment Research raised IntelGenx Technologies Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, June 7th.
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp. is a drug delivery company focusing on the development of orally administered drug delivery products based on its oral drug delivery technologies. The Company is a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets.
Receive News & Ratings for IntelGenx Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.